Ponatinib dosing is indication-specific and must not be interpreted as an individualized prescription. The following reflects the 2025 U.S. ICLUSIG prescribing information. Local labels may differ.
| Treatment setting | Current U.S. labeled starting regimen |
|---|---|
| Newly diagnosed Ph+ ALL + chemotherapy | 30 mg once daily; reduce to 15 mg once daily after MRD-negative CR at end of induction |
| Ph+ ALL monotherapy in specified patients | 45 mg once daily |
| T315I-positive Ph+ ALL | 45 mg once daily |
| CP-CML | 45 mg once daily; reduce to 15 mg once daily after ≤1% BCR::ABL1IS |
| AP-CML | 45 mg once daily |
| BP-CML | 45 mg once daily |
For CP-CML, patients who lose response after reduction may be eligible for re-escalation to a previously tolerated 30 mg or 45 mg dose under the label.
Dose modifications
Ponatinib may require interruption, dose reduction or discontinuation for adverse reactions. Dose modification depends on the type and severity of toxicity.
Hepatic impairment
The U.S. label provides specific dosage modifications for hepatic impairment. These adjustments should be determined using the official prescribing information and clinical assessment.
Drug interactions
Strong CYP3A inhibitors can require dose modification, while strong CYP3A inducers should generally be avoided under current U.S. labeling.
Missed dose
If a dose is missed, the next dose should be taken at the regularly scheduled time the following day; an extra dose should not be taken to compensate.
Jurisdictional limitation
The information above reflects U.S. labeling and should not be assumed to represent prescribing requirements worldwide.